Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 252

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

Open access
Kantarjian, Hagop, Giles, Francis, List, Alan, Lyons, Roger, Sekeres, Mikkael A., Pierce, Sherry, Deuson, Robert, Leveque, Joseph · 2007 · Cancer

Abstract

Thrombocytopenia and platelet dysfunction contribute to hemorrhagic complications in the myelodysplastic syndromes (MDS). Reliable data regarding the frequency and consequences of thrombocytopenia in MDS are lacking. An extensive literature review indicated that the prevalence of thrombocytopenia (platelets <100 × 10 9/L) in MDS ranged from 40% to 65%; the median frequency of thrombocytopenia prior to any MDS therapy was 65% (range, 23–93%). A retrospective review of patients who were referred to the University of Texas M. D. Anderson Cancer Center (MDACC) identified 1605 of 2410 patients (67%) with thrombocytopenia at referral. Of these, 1756 patients were classified using the International Prognostic Scoring System (IPSS), and 896 patients (51%) had intermediate‐2 or high‐risk disease. Treatment‐related thrombocytopenia was observed in studies that involved azacitidine, tipifarnib, decitabine, lenalidomide, sirolimus, and combination chemotherapy with idarubicin, cytarabine, and topotecan. The reported incidence of hemorrhagic complications in the literature ranged from 3% to 53%, and the frequency of hemorrhagic deaths ranged from 14% to 24%. At MDACC, 460 patients had a coded cause of death: hemorrhage as a contributory cause of death, 20%; hemorrhage as the only cause of death, 10%. Thrombocytopenia was common in MDS, and there was an increased prevalence in higher risk IPSS categories. Many approved and investigational MDS therapies caused or exacerbated preexisting thrombocytopenia. The incidence of severe bleeding in MDS was greater than reported in current guidelines. Cancer 2007. © 2007 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.22602

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 252

Metadata

Authors
Kantarjian, H., Giles, F., List, A., Lyons, R., Sekeres, M. A., Pierce, S., Deuson, R., & Leveque, J.
Venue
Cancer
Publisher
Wiley
Published
2007-04-18
Volume
109
Issue
9
Pages
1705-1714
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2125438418
Cited by
252
References
50
FWCI
8.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The incidence and impact of thrombocytopenia in myelodysplastic syndromes. https://app.cochat.ai/papers/10.1002/cncr.22602
The paper
Kantarjian, H., Giles, F., List, A., Lyons, R., Sekeres, M. A., Pierce, S., Deuson, R., & Leveque, J. (2007). The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. https://doi.org/10.1002/cncr.22602

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.